Gufic BioScience

64
Hold
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE742B01025
  • NSEID: GUFICBIO
  • BSEID: 509079
INR
436.05
0.05 (0.01%)
BSENSE

Sep 21, 03:24 PM

BSE+NSE Vol: 60.11 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationCash Flow
Gufic BioScience Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
No of Months
12
12
12
Profit Before Tax
64.00
69.00
86.00
Adjustment
87.00
68.00
63.00
Changes In working Capital
-94.00
7.00
-130.00
Cash Flow after changes in Working Capital
56.00
145.00
19.00
Cash Flow from Operating Activities
45.00
122.00
-7.00
Cash Flow from Investing Activities
-30.00
-70.00
-102.00
Cash Flow from Financing Activities
32.00
-37.00
82.00
Net Cash Inflow / Outflow
46.00
14.00
-27.00
Opening Cash & Cash Equivalents
15.00
1.00
28.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
Closing Cash & Cash Equivalent
62.00
15.00
1.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Gufic BioScience
Markets Mojo
Figures in Cr
consolidated Cash Flow Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Profit Before Tax
64.21
154.2
-90.00
-58.36%
Adjustment
87.6
-17.31
104.00
606.07%
Changes In working Capital
-94.83
-43.17
-51.00
-119.67%
Cash Flow after changes in Working Capital
56.98
93.72
-37.00
-39.20%
Cash Flow from Operating Activities
45.14
56.5
-11.00
-20.11%
Cash Flow from Investing Activities
-30.96
85.84
-115.00
-136.07%
Cash Flow from Financing Activities
32.29
-20.58
52.00
256.90%
Net Cash Inflow / Outflow
46.46
121.76
-75.00
-61.84%
Opening Cash & Cash Equivalents
15.72
28.7
-13.00
-45.23%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
62.19
150.46
-88.00
-58.67%
Cash Flow - Snapshot (Consolidated) - Mar'26
stock-summary

YoY Growth in year ended Mar 2026 is -63.17% vs 1,743.03% in Mar 2025

Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
45.14
122.57
-63.17%